CUBE vs PACB · P/E 25, rev $1.07B vs rev $38.4M
CubeSmart (CUBE) versus Pacific Biosciences of California (PACB) — a side-by-side from cached financials, not a winner call.
CubeSmart (CUBE) is a reit - industrial company listed on US.
Pacific Biosciences of California (PACB) is a medical devices company listed on US.
Latest reported CUBE revenue for 2024-12-31 was $1.07B. Net income was $391.9M. Revenue was up 1.5% from 2023-12-31 to 2024-12-31. CUBE currently screens at market cap $9.69B and trailing P/E 25.0.
Latest reported PACB revenue for 2025-09-30 was $38.4M. Net income was -$38.0M. Revenue was down 3.3% from 2025-06-30 to 2025-09-30. PACB currently screens at market cap $387.1M.
CUBE currently screens at market cap $9.69B and trailing P/E 25.0. PACB currently screens at market cap $387.1M.
Not investment advice. Open the CUBE and PACB stock pages for the full models.
Not investment advice.